Tiziana life sciences announces timetable of demerger of accustem (for holders of tiziana adrs)

New york and london, oct. 27, 2020 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / aim: tils) ("tiziana" or the "company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the accustem sciences limited ("accustem") demerger (the "demerger") for holders of the company's american depositary receipts (“adrs”).
TLSA Ratings Summary
TLSA Quant Ranking